If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPTY.L Regulatory News (PTY)

  • There is currently no data for PTY

Director/PDMR Shareholding

18 Apr 2019 11:37

RNS Number : 6520W
Parity Group PLC
18 April 2019
 

18 April 2019

 

Parity Group plc ("Parity "or the "Group")

Grant of Options to Directors/PDMRs

 

The Board of Parity (AIM:PTY), the technology focussed consultancy and staffing business announces that the Board has awarded Matthew Bayfield, Chief Executive Officer 3,000,000 ordinary shares of 2 pence each in the Company ("Share Options"). The Share Options were granted on 18 April 2019 on the recommendation of the Remuneration Committee, and represent approximately 2.9% of the Company's current issued share capital.

 

The Share Options each have an exercise price, calculated in accordance with the rules of the Unapproved CSOP Scheme 2009, of 7.75 pence being the closing mid-market price per ordinary share on 17 April 2019.

 

The Share Options will vest after 3 years and are subject to the following performance conditions:

 

· One third of the Share Options will be exercisable if the share price achieves or exceeds 125% of the exercise price for a period of at least five consecutive trading days at any time during the vesting period;

· One third of the Share Options will be exercisable if the share price achieves or exceeds 150% of the exercise price for a period of at least five consecutive trading days at any time during the vesting period; and

· One third of the Share Options will be exercisable if the share price achieves or exceeds 175% of the exercise price for a period of at least five consecutive trading days at any time during the vesting period.

 

 

 

 

Contacts:

Parity Group PLC www.parity.net

Roger Antony, GFD + 44 (0) 208 543 5353

 

WH Ireland Limited www.whirelandcb.com

Mike Coe / Chris Savidge +44 (0) 207 220 1666

 

 

The notifications below, made in accordance with the EU Market Abuse Regulation, provide further details in relation to the grant of the Share Options to the PDMRs:

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

Matthew Bayfield

2

 

Reason for the notification

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

 

Parity Group plc

b)

 

LEI

213800YEHAYBJ63OHB38

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Ordinary shares of 2p each

 

GB00B1235860

b)

 

Nature of the transaction

 

Grant of options to subscribe for new ordinary shares under the Company's Unapproved CSOP Scheme 2009.

c)

 

Price(s) and volume(s)

 

Option Price(s)

 

Volume(s)

7.75p

3,000,000

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

- Price

 

 

 

3,000,000

 

ÂŁ232,500.00

 

e)

 

Date of the transaction

18 April 2019

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHCKFDNKBKDPQD
Date   Source Headline
23rd Jul 20087:00 amRNSAcquisition of Parity Trainin
23rd Jul 20087:00 amRNSTrading Statement
23rd Jul 20087:00 amRNSDisposal of Parity Training L
2nd Jul 20081:57 pmRNSHolding(s) in Company
30th Jun 20084:54 pmRNSHolding(s) in Company
10th Jun 20087:00 amRNSCharity Commission Contract E
14th May 200812:51 pmRNSResult of AGM
2nd May 20087:00 amRNSInterim Management Statement
23rd Apr 20084:10 pmRNSDirector/PDMR Shareholding
21st Apr 20083:37 pmRNSAnnual Report and Accounts
31st Mar 20085:02 pmRNSDirector/PDMR Shareholding
18th Mar 20082:20 pmRNSHolding(s) in Company
18th Mar 20082:15 pmRNSHolding(s) in Company
5th Mar 20087:00 amRNSFinal Results
7th Jan 20087:00 amRNSTrading Statement
6th Nov 20074:35 pmRNSDirector/PDMR Shareholding
2nd Nov 20072:19 pmRNSDirector/PDMR Shareholding
1st Nov 20079:49 amRNSDirector/PDMR Shareholding
31st Oct 200710:06 amRNSTotal Voting Rights
25th Oct 20072:23 pmRNSDoc re. Interim Report 2007
17th Oct 20071:56 pmRNSAdditional Listing
17th Oct 20077:00 amRNSDirectorate Change
8th Oct 20073:53 pmRNSHolding(s) in Company
8th Oct 20073:50 pmRNSHolding(s) in Company
13th Sep 200711:12 amRNSHolding(s) in Company
12th Sep 20077:01 amRNSInterim Results
17th Aug 20077:00 amRNSNotice of Results
19th Jun 20075:56 pmRNSHolding(s) in Company
13th Jun 20074:58 pmRNSResult of AGM
13th Jun 200711:00 amRNSDirectorate Change
13th Jun 200711:00 amRNSAGM Statement
5th Jun 20073:25 pmRNSDirector/PDMR Shareholding
4th Jun 20077:01 amRNSRe Contract
1st Jun 200711:09 amRNSAnnual Information Update
17th May 200712:30 pmRNSDirectorate Change
10th May 20071:30 pmRNSDirector/PDMR S/hldg/Amend
8th May 20072:28 pmRNSHolding(s) in Company
1st May 20079:02 amRNSDirector/PDMR Shareholding
21st Mar 200712:16 pmRNSHolding(s) in Company
19th Mar 20075:02 pmRNSHolding(s) in Company
14th Mar 20077:02 amRNSFinal Results
1st Mar 20079:46 amRNSNotice of Results
22nd Feb 20072:21 pmRNSHolding(s) in Company
29th Jan 20072:18 pmRNSHolding(s) in Company
22nd Jan 20079:43 amRNSTotal Voting Rights
17th Jan 200712:24 pmRNSAdditional Listing
5th Jan 20072:47 pmRNSHolding(s) in Company
20th Dec 20064:43 pmRNSHolding(s) in Company
19th Dec 20063:54 pmRNSTotal Voting Rights
18th Dec 20067:01 amRNSRe Contract

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.